Our Goal

Osivax is transforming the vaccine development landscape through its novel, proprietary oligoDOM® technology platform and universal vaccine candidates designed to provide long-term protection against highly mutating viruses such as influenza and coronavirus.

About us

Led by a well-established team of corporate and clinical development experts, Osivax is leveraging its oligoDOM® platform to develop universal vaccines for current and future strains of influenza along with existing and emerging coronavirus infections. Osivax is focused on providing proof-of-concept in these indications, with plans to apply its technology broadly to other infectious diseases.
Alexandre Le Vert​
CEO of Osivax

“Osivax strives to transform the high-value vaccine development landscape and improve global health through a game-changing technology designed to provide long-term protection against highly mutating viruses. We have assembled a strong and highly capable team of experts collectively dedicated to making universal vaccines available to people worldwide.”

Jeffrey Almond
Chairman of the Osivax Scientific Advisory Board

“With the oligoDOM® self-assembling nanoparticle technology, Osivax is unlocking an approach that enables the generation of T-cell responses against highly conserved internal antigens, a rare capability not found in many other nanoparticle technologies. This tactic may facilitate the development of universal vaccines to protect against current and future strains or antigenic variants of a particular virus. I am impressed by the results obtained with OVX836 in preclinical and clinical trials over the past few years and by the recent progress in other indications which show the potential of the oligoDOM® platform.”

Geert Leroux
Member of the Osivax Clinical Advisory Board

“Osivax is building upon its cutting-edge technology oligoDOM®, an approach that triggers strong cellular immune responses against internal and conserved antigens of viruses to develop universal vaccines against all current and future virus strains or variants. In Flu, the phase 1 and phase 2a clinical trials with more than 350 subjects demonstrated a good safety profile, strong NP-specific cellular immune responses and a first signal of efficacy in the phase 2a trial. These results are very promising, de-risking the technology and paving the way for a field efficacy trial.”